FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a tre...
Journal of veterinary internal medicine2022; 36(3); 1179-1184; doi: 10.1111/jvim.16425

ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study.

Abstract: Sarcoid tumors are common in horses and may negatively impact the performance and value of the horse. No known treatment is reliably successful. Objective: To determine tolerability, overall response rate, time to response, and progression-free survival of horses with biopsy-confirmed or suspected sarcoids treated with ALVAC-fIL2. Methods: Client-owned horses with measurable, presumed- or biopsy-confirmed sarcoid tumors. Methods: Prospective pilot study. One milliliter of ALVAC-fIL2 was injected into 4 to 5 areas of the sarcoid(s) in each horse (week 0); this treatment was repeated in weeks 1, 3, and 7. Sarcoids were measured at each visit, and response to treatment was determined according to the Response Evaluation Criteria in Solid Tumors for dogs (v1.0). After the final treatment, horses were reassessed and sarcoids remeasured every 3 months until tumor progression or for a minimum of 1 year if progression was not documented. Results: Fourteen horses were included. Tumor size decreased in 86% of the horses, and the median time to first response was 89 days (range, 34-406 days). Median time to best response was 211 days (range, 56-406 days), but 3 of the sarcoids still were decreasing in size at the time of final evaluation. The median progression-free interval was not reached. Adverse events were minimal and included transient focal inflammation in 2 horses. Conclusions: Intratumoral injection of ALVAC-fIL2 has promise as a well-tolerated and effective, tissue-sparing treatment for horses with sarcoid tumors.
© 2022 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2022-04-13 PubMed ID: 35416353PubMed Central: PMC9151478DOI: 10.1111/jvim.16425Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article explores the effectiveness of ALVAC-fIL2, a feline interleukin-2 immunomodulator, in treating sarcoid tumors in horses. The study found the treatment to be generally well-tolerated, with tumor size decreasing in a majority of cases.

Objective and Methods

  • The objective of this study was to determine the tolerability, overall response rate, time to response, and progression-free survival of horses with either presumed or biopsy-confirmed sarcoid tumors treated with ALVAC-fIL2.
  • The researchers conducted a prospective pilot study, using client-owned horses diagnosed with measurable sarcoid tumors.
  • The treatment involved injecting 1 milliliter of ALVAC-fIL2 into 4 to 5 areas of the sarcoid(s) in each horse. This process was repeated at varying intervals – at the start (week 0), and subsequently in the first, third, and seventh weeks.
  • The researchers measured the sarcoids in each horse at every visit and determined the response to treatment using the Response Evaluation Criteria in Solid Tumors for dogs (version 1.0).
  • After the final treatment, the horses’ sarcoids were reassessed and remeasured every three months until there was evidence of tumor progression, or for a minimum of one year if no progression was documented.

Key Findings

  • Fourteen horses were included in the study. Of these, 86% exhibited a decrease in tumor size and the median time to first response was 89 days. The time taken ranged between minimum of 34 days to a maximum of 406 days.
  • The median time to observe the best response was 211 days, although 3 sarcoids were still shrinking at the time of the final evaluation.
  • The median progression-free interval was not reached, implying ongoing effectiveness of the treatment beyond the period of observation.
  • Adverse events were minimal. Only two horses experienced transient focal inflammation as a side effect.

Conclusion

  • The study concluded that the intratumoral injection of ALVAC-fIL2 has potential as a well-tolerated and effective treatment for horses with sarcoid tumors.
  • Aside from being effective, it’s also a tissue-sparing treatment, which can be advantageous in preserving the health and performance of the horse.

Cite This Article

APA
Saba C, Eggleston R, Parks A, Peroni J, Sjoberg E, Rice S, Tyma J, Williams J, Grosenbaugh D, Leard AT. (2022). ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study. J Vet Intern Med, 36(3), 1179-1184. https://doi.org/10.1111/jvim.16425

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 36
Issue: 3
Pages: 1179-1184

Researcher Affiliations

Saba, Corey
  • Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Eggleston, Randall
  • Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Parks, Andrew
  • Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Peroni, John
  • Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Sjoberg, Eric
  • Maggie's Menagerie Veterinary Services, Ila, Georgia, USA.
Rice, Shelbe
  • Maggie's Menagerie Veterinary Services, Ila, Georgia, USA.
Tyma, Jesse
  • Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Williams, Jarred
  • Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Grosenbaugh, Deborah
  • Boehringer Ingelheim Animal Health, Athens, Georgia, USA.
Leard, A Timothy
  • Boehringer Ingelheim Animal Health, Athens, Georgia, USA.

MeSH Terms

  • Adjuvants, Immunologic
  • Animals
  • Horse Diseases / drug therapy
  • Horses
  • Immunologic Factors / therapeutic use
  • Interleukin-2
  • Pilot Projects
  • Prospective Studies
  • Sarcoidosis / drug therapy
  • Sarcoidosis / veterinary

Grant Funding

  • Boehringer Ingelheim

Conflict of Interest Statement

Drs Grosenbaugh and Leard were employed by Boehringer Ingelheim Animal Health at the time this study was performed.

References

This article includes 38 references
  1. Schaffer PA, Wobeser B, Martin LE, Dennis MM, Duncan CG. Cutaneous neoplastic lesions of equids in the central United States and Canada: 3,351 biopsy specimens from 3,272 equids (2000-2010).. J Am Vet Med Assoc 2013 Jan 1;242(1):99-104.
    pubmed: 23234288doi: 10.2460/javma.242.1.99google scholar: lookup
  2. Bergvall KE. Sarcoids.. Vet Clin North Am Equine Pract 2013 Dec;29(3):657-71.
    pubmed: 24267682doi: 10.1016/j.cveq.2013.09.002google scholar: lookup
  3. Goodrich L, Gerber H, Marti E, Antczak DF. Equine sarcoids.. Vet Clin North Am Equine Pract 1998 Dec;14(3):607-23, vii.
    pubmed: 9891727doi: 10.1016/s0749-0739(17)30189-xgoogle scholar: lookup
  4. Haspeslagh M, Jordana Garcia M, Vlaminck LEM, Martens AM. Topical use of 5% acyclovir cream for the treatment of occult and verrucous equine sarcoids: a double-blinded placebo-controlled study.. BMC Vet Res 2017 Oct 6;13(1):296.
    pmc: PMC6389201pubmed: 28985733doi: 10.1186/s12917-017-1215-0google scholar: lookup
  5. Rothacker CC, Boyle AG, Levine DG. Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009-2014).. Can Vet J 2015 Jul;56(7):709-14.
    pmc: PMC4466821pubmed: 26130832
  6. Haspeslagh M, Vlaminck LE, Martens AM. Treatment of sarcoids in equids: 230 cases (2008-2013).. J Am Vet Med Assoc 2016 Aug 1;249(3):311-8.
    pubmed: 27439349doi: 10.2460/javma.249.3.311google scholar: lookup
  7. Compston PC, Turner T, Wylie CE, Payne RJ. Laser surgery as a treatment for histologically confirmed sarcoids in the horse.. Equine Vet J 2016 Jul;48(4):451-6.
    pubmed: 25959259doi: 10.1111/evj.12456google scholar: lookup
  8. Nogueira SA, Torres SM, Malone ED, Diaz SF, Jessen C, Gilbert S. Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study.. Vet Dermatol 2006 Aug;17(4):259-65.
    pubmed: 16827669doi: 10.1111/j.1365-3164.2006.00526.xgoogle scholar: lookup
  9. Théon AP, Pascoe JR. Iridium-192 interstitial brachytherapy for equine periocular tumours: treatment results and prognostic factors in 115 horses.. Equine Vet J 1995 Mar;27(2):117-21.
    pubmed: 7607143doi: 10.1111/j.2042-3306.1995.tb03046.xgoogle scholar: lookup
  10. Byam-Cook KL, Henson FM, Slater JD. Treatment of periocular and non-ocular sarcoids in 18 horses by interstitial brachytherapy with iridium-192.. Vet Rec 2006 Sep 9;159(11):337-41.
    pubmed: 16963712doi: 10.1136/vr.159.11.337google scholar: lookup
  11. Berruex F, Gerber V, Wohlfender FD, Burger D, Koch C. Clinical course of sarcoids in 61 Franches-Montagnes horses over a 5-7 year period.. Vet Q 2016 Dec;36(4):189-196.
    pubmed: 27327513doi: 10.1080/01652176.2016.1204483google scholar: lookup
  12. Dhupkar P, Gordon N. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.. Adv Exp Med Biol 2017;995:33-51.
    pubmed: 28321811doi: 10.1007/978-3-319-53156-4_2google scholar: lookup
  13. Steinbach F, Bischoff S, Freund H, Metzner-Flemisch S, Ibrahim S, Walter J, Wilke I, Mauel S. Clinical application of dendritic cells and interleukin-2 and tools to study activated T cells in horses--first results and implications for quality control.. Vet Immunol Immunopathol 2009 Mar 15;128(1-3):16-23.
    pubmed: 19056130doi: 10.1016/j.vetimm.2008.10.317google scholar: lookup
  14. Spoormakers TJ, Klein WR, Jacobs JJ, Van Den Ingh TS, Koten JW, Den Otter W. Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2.. Cancer Immunol Immunother 2003 Mar;52(3):179-84.
    pubmed: 12649747doi: 10.1007/s00262-002-0369-0google scholar: lookup
  15. Langan EA, Kümpers C, Graetz V, Perner S, Zillikens D, Terheyden P. Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma.. Dermatol Ther 2019 May;32(3):e12901.
    pubmed: 30974014doi: 10.1111/dth.12901google scholar: lookup
  16. Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry.. J Immunother Cancer 2019 Mar 27;7(1):84.
    pmc: PMC6437874pubmed: 30917871doi: 10.1186/s40425-019-0567-3google scholar: lookup
  17. Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.. J Immunother Cancer 2019 Feb 18;7(1):49.
    pmc: PMC6380045pubmed: 30777131doi: 10.1186/s40425-019-0522-3google scholar: lookup
  18. Haagsman AN, Witkamp AC, Sjollema BE, Kik MJ, Kirpensteijn J. The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study.. BMC Vet Res 2013 Aug 8;9:155.
    pmc: PMC3751239pubmed: 23927575doi: 10.1186/1746-6148-9-155google scholar: lookup
  19. DEN Otter W, Hack M, Jacobs JJ, Tan JF, Rozendaal L, VAN Moorselaar RJ. Effective Treatment of Transmissible Venereal Tumors in Dogs with Vincristine and IL2.. Anticancer Res 2015 Jun;35(6):3385-91.
    pubmed: 26026099
  20. Loschelder-Ostrowski J, Winter JC, Merle R, Klopfleisch R, Gehlen H. Treatment of equine sarcoids using recombinant poxviruses expressing feline interleukin-2.. Vet Dermatol 2021 Jun;32(3):283-e77.
    pubmed: 33728715doi: 10.1111/vde.12941google scholar: lookup
  21. Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.. Vet Comp Oncol 2015 Sep;13(3):176-83.
    pubmed: 23534501doi: 10.1111/vco.12032google scholar: lookup
  22. . Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1.. Vet Comp Oncol 2016 Dec;14(4):417-446.
    pubmed: 28530307doi: 10.1111/vco.283google scholar: lookup
  23. Martens A, De Moor A, Demeulemeester J, Peelman L. Polymerase chain reaction analysis of the surgical margins of equine sarcoids for bovine papilloma virus DNA.. Vet Surg 2001 Sep-Oct;30(5):460-7.
    pubmed: 11555822doi: 10.1053/jvet.2001.25874google scholar: lookup
  24. Ragland WL, Keown GH, Spencer GR. Equine sarcoid.. Equine Vet J 1970;2:2‐11.
  25. Carstanjen B, Jordan P, Lepage OM. Carbon dioxide laser as a surgical instrument for sarcoid therapy--a retrospective study on 60 cases.. Can Vet J 1997 Dec;38(12):773-6.
    pmc: PMC1576782pubmed: 9426943
  26. Martens A, De Moor A, Vlaminck L, Pille F, Steenhaut M. Evaluation of excision, cryosurgery and local BCG vaccination for the treatment of equine sarcoids.. Vet Rec 2001 Dec 1;149(22):665-9.
    pubmed: 11765322doi: 10.1136/vr.149.22.665google scholar: lookup
  27. Klein WR, Bras GE, Misdorp W, Steerenberg PA, de Jong WH, Tiesjema RH, Kersjes AW, Ruitenberg EJ. Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial.. Cancer Immunol Immunother 1986;21(2):133-40.
    pubmed: 3633215doi: 10.1007/bf00199861google scholar: lookup
  28. Knottenbelt DC, Kelly DF. The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999.. Vet Ophthalmol 2000;3(2-3):169-191.
    pubmed: 11397301doi: 10.1046/j.1463-5224.2000.00119.xgoogle scholar: lookup
  29. Lavach JD, Sullins KE, Roberts SM, Severin GA, Wheeler C, Lueker DC. BCG treatment of periocular sarcoid.. Equine Vet J 1985 Nov;17(6):445-8.
    pubmed: 4076159doi: 10.1111/j.2042-3306.1985.tb02552.xgoogle scholar: lookup
  30. Melero I, Navarro B, Teijeira A, Coukos G. Cancer immunotherapy full speed ahead.. Ann Oncol 2017 Dec 1;28(suppl_12):xii1-xii2.
    pubmed: 29253117doi: 10.1093/annonc/mdx739google scholar: lookup
  31. Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I. Targeting NK-cell checkpoints for cancer immunotherapy.. Curr Opin Immunol 2017 Apr;45:73-81.
    pubmed: 28236750doi: 10.1016/j.coi.2017.01.003google scholar: lookup
  32. Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.. J Immunother Cancer 2019 Jan 9;7(1):6.
    pmc: PMC6325819pubmed: 30626434doi: 10.1186/s40425-018-0495-7google scholar: lookup
  33. Poulet H, Minke J, Pardo MC, Juillard V, Nordgren B, Audonnet JC. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.. Vaccine 2007 Jul 26;25(30):5606-12.
    pubmed: 17227690doi: 10.1016/j.vaccine.2006.11.066google scholar: lookup
  34. Taylor J, Tartaglia J, Rivière M, Duret C, Languet B, Chappuis G, Paoletti E. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination.. Dev Biol Stand 1994;82:131-5.
    pubmed: 7958467
  35. Jourdier TM, Moste C, Bonnet MC, Delisle F, Tafani JP, Devauchelle P, Tartaglia J, Moingeon P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).. Gene Ther 2003 Dec;10(26):2126-32.
    pubmed: 14625567doi: 10.1038/sj.gt.3302124google scholar: lookup
  36. Jas D, Soyer C, De Fornel‐Thibaud P. Adjuvant immunotherapy of feline injection‐site sarcomas with the recombinant canarypox virus expressing feline interleukine‐2 evaluated in a controlled monocentric clinical trial when used in association with surgery and brachytherapy.. Trials Vaccinol 2015;4:1‐8.
  37. Ferrari G, Berend C, Ottinger J, Dodge R, Bartlett J, Toso J, Moody D, Tartaglia J, Cox WI, Paoletti E, Weinhold KJ. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.. Blood 1997 Sep 15;90(6):2406-16.
    pubmed: 9310492
  38. Koch C, Martens A, Hainisch EK, Schüpbach G, Gerber V, Haspeslagh M. The clinical diagnosis of equine sarcoids - Part 1: Assessment of sensitivity and specificity using a multicentre case-based online examination.. Vet J 2018 Dec;242:77-82.
    pubmed: 30195623doi: 10.1016/j.tvjl.2018.08.009google scholar: lookup

Citations

This article has been cited 5 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.